Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 759 results
Filters: First Letter Of Title is R  [Clear All Filters]
Found 759 results.

Adipose Tissue

Shikuma CM, Gangcuangco LMar A, Killebrew DA, et al. "The role of HIV and monocytes/macrophages in adipose tissue biology." J. Acquir. Immune Defic. Syndr.. 2014;65(2):151-9.

Adolescent

Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Simoni JM, Huh D, Wilson IB, et al. "Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study." J. Acquir. Immune Defic. Syndr.. 2012;60(5):466-72.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.

Adult

Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Albrecht M, A Mukherjee L, Tierney C, et al. "A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study." HIV Clin Trials. 2011;12(4):201-14.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
Peters MG, Andersen J, Lynch P, et al. "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127." Hepatology. 2006;44(5):1110-6.
Currier JS, Britto P, Hoffman RM, et al. "Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3." PLoS ONE. 2017;12(5):e0176009.
Wilkin TJ, Goetz MBidwell, Leduc R, et al. "Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity." Clin. Infect. Dis.. 2011;52(7):925-8.
Mollan KR, Tierney C, Hellwege JN, et al. "Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants." J. Infect. Dis.. 2017;216(5):554-564.
Demeter LM, Jiang H, A Mukherjee L, et al. "A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients." AIDS. 2009;23(3):357-68.
Kendall MA, Andersen JW, van der Horst C. "A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207." Contemp Clin Trials. 2006;27(3):287-94.
Ribaudo HJ, Smith KY, Robbins GK, et al. "Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis." Clin. Infect. Dis.. 2013;57(11):1607-17.
Paul RH, Ernst T, Brickman AM, et al. "Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV." J Int Neuropsychol Soc. 2008;14(5):725-33.
Gandhi RT, O'Neill D, Bosch RJ, et al. "A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy." Vaccine. 2009;27(43):6088-94.
Longenecker CT, Kitch D, Sax PE, et al. "Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s." J. Acquir. Immune Defic. Syndr.. 2015;69(2):168-77.

Pages